[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-valve-prolapse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-valve-prolapse":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,64,85,108,139,166,194,219,241,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100545215","arrhythmic-mitral-valve-prolapse-detection-using-long-term-ambulatory-rhythm-monitoring-100545215",false,"NCT06378996","Arrhythmic Mitral Valve Prolapse Detection Using Long-term Ambulatory Rhythm Monitoring","Arrhythmic Mitral Valve Prolapse Detection Using Long-term Ambulatory Rhythm - A Pilot Study","ALARM-PILOT","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Mitral valve prolapse diagnosed on previous echocardiography or cardiac MRI\n* New York Heart association classification ≥3 for cohort 3 and classification 1 or 2 for cohorts 1 and 2\n* Willing and able to provide signed written informed consent\n* No contra-indication for long-term monitoring (known allergy to adhesives)\n\nExclusion Criteria:\n\n* Prior cardiac surgery, including previous mitral valve intervention\n* Prior endovascular mitral valve repair (MitraClip)\n* Previous catheter ablation of ventricular arrhythmias\n* Patients not in sinus rhythm\n* Patients on anti-arrhythmic drugs but betablockers\n* Known alternative arrhythmic substrate, for example previous myocardial infarction\n* Known allergy to adhesives","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Mitral valve prolapse (MVP) affects up to 3% of the general population and a small subset of patients is at risk for ventricular arrhythmias. This subgroup is referred to as AMVP (arrhythmic MVP) and was recently defined using the following criteria: (1) Presence of MVP), (2) Ventricular arrhythmia that is either frequent (≥5% total premature ventricular contraction (PVC) burden on Holter) or complex (non-sustained ventricular tachycardia (nsVT), ventricular tachycardia (VT), or ventricular fibrillation (VF)), and (3) The absence of any other well-defined arrhythmic substrate.\n\nCurrently, diagnosis is often based on repeated 24-hour Holter monitoring. However, the ventricular arrhythmia burden varies from day-to-day and long-term rhythm monitoring has shown in other pathologies to increase the diagnostic yield with up to 200% (from 22.5% on 24h to 75.3% on 14 days).\n\nThis pilot study aims to study the diagnostic yield of long-term rhythm monitoring in patients with MVP as well as the day-to-day variability of ventricular arrhythmias to facilitate power calculation for a future large-scale prospective registry.",[27,28],"Mitral Valve Prolapse","Ventricular Arrythmia","RECRUITING","2026-04-28",{"date":32,"type":33},"2026-05-05","ACTUAL",{"date":35,"type":33},"2024-05-01",{"date":37,"type":21},"2026-06",{"name":39,"class":40},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100542307","multiparametric-scores-for-prediction-of-myocardial-fibrosis-in-patients-with-mitral-valve-prolapse-100542307","NCT06341166","Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse","Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse: the SCIMITAR Trial","SCIMITAR","Inclusion Criteria:\n\n* age ≥ 18 years\n* Echocardiographic diagnosis of mitral valve prolaspe, defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the mitral valve annulus in long-axis views\n\nExclusion Criteria:\n\n* age\\\u003C 18 years\n* coexistence of other cardiomyopathies or other ≥ moderate valve diseases\n* scarce acoustic transthoracic echocardiographic window\n* usual contraindications for cardiac magnetic resonance",{"count":51,"type":21},300,"OBSERVATIONAL","This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP.",[27],"2026-01-30",{"date":57,"type":33},"2026-02-03",{"date":59,"type":33},"2023-06-19",{"date":61,"type":21},"2026-06-19",{"name":63,"class":40},"Centro Cardiologico Monzino",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":41},"100622534","ai-based-shape-and-function-analysis-of-mitral-valve-prolapse-using-3d-ultrasound-100622534","NCT07384871","AI-Based Shape and Function Analysis of Mitral Valve Prolapse Using 3D Ultrasound","AI-Based Morphological Analysis and Biomechanical Numerical Evaluation of Mitral Valve Prolapse (MVP) From Real-Time 3D Echocardiography (RT3DE)","AI4MVP","Inclusion Criteria:\n\n* Adult patients (age \\> 18 years old);\n* Documented symptomatic degenerative MR with indication to MVP surgical repair, following the Heart Team decision;\n* Periprocedural transesophageal 3DRTE of the MV apparatus, which is clinical standard modality for morphological assessment and guidance during MVP surgical repair;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Inadequate quality of 3DRTE imaging, e.g., due to inadequate patient-specific acoustic window;\n* 3DRTE imaging with a temporal resolution of \\\u003C 20 Hz;\n* Patient treated through prosthetic MV replacement.",{"count":73,"type":21},150,"This study aims to develop and validate a fully automated imaging and modeling pipeline for the analysis of mitral valve prolapse (MVP) using real-time three-dimensional transesophageal echocardiography (RT3DE). The primary goal is to automatically segment mitral valve (MV) substructures, extract anatomical landmarks, and generate 3D models of the MV apparatus to characterize morphological and functional features of degenerative MVP. Advanced deep learning techniques and geometric processing tools will be applied to enable automated analysis.\n\nA secondary objective is to build patient-specific finite element (FE) models based on RT3DE data to evaluate the biomechanical consequences of MVP and to simulate the effects of surgical repair. These simulations will assess stress distribution and force transmission within the MV apparatus.\n\nAdditionally, in cases where substantial surgical resection of MV tissue occurs, excised leaflet samples will be collected and preserved for histological and morphometric analysis.",[27,76],"Myxomatous Mitral Valve Degeneration","2026-01-26",{"date":57,"type":33},{"date":80,"type":33},"2025-05-26",{"date":82,"type":21},"2028-05",{"name":84,"class":40},"IRCCS Policlinico S. Donato",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":41},"100535717","ventricular-arrhythmias-in-patients-undergoing-mitral-valve-surgery-100535717","NCT06255457","Ventricular Arrhythmias in Patients Undergoing Mitral Valve Surgery","Mechanisms and Outcomes in Patients With Arrhythmic Mitral Valve Prolapse Undergoing Mitral Valve Surgery","Mitra-VT","Inclusion criteria\n\n* Age 18 and over\n* Patients with and without (controls) arrhythmogenic MVP in need of mitral valve surgery for primary mitral regurgitation according to current standard of care\n\nExclusion criteria\n\n* Secondary mitral regurgitation\n* Primary mitral regurgitation not due to degenerative disease (including rheumatic disease)\n* Co-existing moderate or severe aortic valve disease\n* Congenital heart disease\n* Inherited or acquired cardiomyopathy\n* Non-incidental or symptomatic coronary artery disease\n* Uncontrolled atrial fibrillation (resting heart rate \\> 100\u002Fmin)\n* Pregnancy\n* Unable to undergo CMR",{"count":94,"type":21},90,"Study objectives:\n\n* To assess the impact of mitral valve surgery for mitral regurgitation on ventricular arrhythmic burden and surrogate markers of fibrosis in patients with arrhytmogenic mitral valve prolapse (MVP) from baseline to 6 months after surgery\n* To characterize the molecular landscape of arrhytmogenic MVP\n\nStudy design:\n\n-Prospective explorative observational study\n\nStudy population:\n\n-90 patients with arrhytmogenic MVP and without arrhytmogenic MVP (controls) eligible for mitral valve surgery for mitral regurgitation will be enrolled. All patients will be evaluated with cardiac magnetic resonance (CMR) imaging and continuous seven day arrhythmic monitoring before and at 6 months after mitral valve surgery",[97,27,98],"Mitral Regurgitation","Ventricular Tachycardia","2025-09-04",{"date":101,"type":33},"2025-09-11",{"date":103,"type":33},"2024-02-21",{"date":105,"type":21},"2026-03-01",{"name":107,"class":40},"Karolinska Institutet",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100600918","primary-ancillary-substudy-100600918","NCT07103733","PRIMARY Ancillary Substudy","Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) Ancillary Substudy","Inclusion Criteria:\n\n* Patients who meet all eligibility criteria and are randomized in the parent PRIMARY trial.\n* For the ancillary biospecimen study, patients who are randomized to MVr in the parent trial.\n\nExclusion Criteria:\n\n* Severe claustrophobia not controlled with sedation.\n* Prior adverse reaction to gadolinium administration.\n* Patients with an implantable subcutaneous cardioverter defibrillator and\u002For cardiac resynchronization therapy device with defibrillator may be excluded as they typically produce substantial artifacts on cardiac MRI making assessment very challenging.\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies (for patients undergoing rhythm monitoring).","60 Years",{"count":117,"type":21},250,[24],"The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological processes by which mitral valve prolapse (MVP) can impact left ventricular (LV) myocardial structure and function, and, thereby, predispose to arrhythmias and sudden death. Such insights are key to identifying interventions to reduce the long-term sequelae of heart failure (HF) and arrhythmias, as well as delineate optimal therapeutic approaches for different patient sub-groups.",[27,121,122],"Left Ventricular Fibrosis","Ventricular Arrhythmias",[124,125,126,127,128],"Mitral valve repair (MVr)","Transcatheter-edge-to-edge-repair (TEER)","Cardiac magnetic resonance imaging (CMR)","ZioPatch monitoring","Heart biopsy","2025-08-14",{"date":131,"type":33},"2025-08-19",{"date":133,"type":33},"2023-10-16",{"date":135,"type":21},"2027-06-30",{"name":137,"class":40},"Annetine Gelijns",25,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":41},"100487794","phase-3-effect-and-safety-of-flecainide-and-metoprolol-versus-metoprolol-alone-to-suppress-ventricular-arrhythmias-in-arrhythmic-mitral-valve-prolapse-100487794","NCT05631730","Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","An Investigator-Initiated Prospective Randomized Open-Label Blinded-Endpoint Crossover Trial Comparing the Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","FLECAPRO","Inclusion Criteria:\n\n* Participants must be 18 years of age or older at the time of signing the informed consent.\n* Participants must have mitral valve prolapse evident by echocardiography or cardiac magnetic resonance imaging, defined as more than or equal to 2 mm atrial displacement of any part of the mitral leaflets.\n* Participants must have ventricular arrhythmias, defined as at least one of the following (i) premature ventricular complex burden ≥3% per 24 hours by Holter monitoring, (ii) premature ventricular complex burden ≥1% per 24 hours if multifocal or occurring in bi-\u002Ftrigemini and\u002For couplets by Holter monitoring, (iii) sustained or non-sustained ventricular tachycardia, (iv) aborted cardiac arrest.\n* Participants must have a clinical indication for antiarrhythmic treatment due to ventricular arrhythmias.\n* Participants must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n* Participants (only women of childbearing) must accede to mandatory use of a contraceptive method for the duration of the trial and until 3 days after discontinuation of study medication.\n\nExclusion Criteria:\n\n* Strict contraindications to flecainide or metoprolol use\n* Heart failure (signs or symptoms, elevated N-terminal proBNP)\n* Abnormal liver or kidney function (Aspartate aminotransferase (AST)\u002FAlanine aminotransferase (ALT) three times upper normal, estimated glomerular filtration (eGRF) \\\u003C60)\n* Prior myocardial infarction or ischemic heart disease\n* Ion channelopathy, including Brugada syndrome and long QT syndrome\n* Genetic cardiomyopathy (hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, including genotype positive phenotype negative individuals)\n* Atrial flutter or permanent atrial fibrillation\n* Sinus node dysfunction\n* Ongoing electrolyte disorders\n* More than moderate valvular disease according to international guidelines\n* Pre-excitation\n* Any degree of AV-block, except due to enhanced vagal tone (e.g. Wenckebach-block at night in young athletes or 1st-degree AV block that disappears during exercise)\n* Bundle branch block (QRS duration \\>120 ms) or intraventricular conduction defect with QRS \\>120 ms.\n* Prior flecainide therapy.\n* Concomitant use of the following medications (i) CYP2D6 inhibitors\u002Finducers, (ii) class I, III or IV antiarrhythmic drugs, (iii) clozapine, quinidine, cimetidine, bupropion, or (iii) monoamineoxidase (MAO) inhibitors\n* Pregnancy\n* Not willing to use a mandatory contraceptive method for the duration of the trial.",{"count":148,"type":21},50,[150],"PHASE3","FLECAPRO is a randomized controlled crossover trial assessing the effect and safety of adding flecainide to standard beta-blocker therapy to reduce the burden of ventricular arrhythmias in patients with arrhythmic mitral valve prolapse. The primary endpoint of will be assessed using an implantable loop recorder with blinded endpoint adjudication.",[27,153],"Ventricular Arrhythmias and Cardiac Arrest",[155,156,157],"arrhythmic mitral valve prolapse","mitral annular disjunction","ventricular arrhythmia","2025-07-29",{"date":160,"type":33},"2025-07-30",{"date":162,"type":33},"2023-01-04",{"date":37,"type":21},{"name":165,"class":40},"Oslo University Hospital",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100598218","korea-vhd-echo-study-surveillance-of-aortic-mitral--tricuspid-patients---insights-from-real-world-practice-100598218","NCT07068633","Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice","Inclusion Criteria:\n\n* Period: 2010.1.1\\~2020.12.31\n* Age \\> 18 years\n* Moderate or severe native VHD (AS, AR, MR and TR)\n* Perform echocardiography more than twice\n\nExclusion Criteria:\n\n* Poor image of echocardiography\n* Follow up loss","19 Years",{"count":174,"type":21},30000,"Valvular heart disease (VHD) is a growing public health concern globally, with increasing disease burden and rising interest in advanced treatment strategies such as transcatheter interventions. However, there remains a significant lack of real-world data regarding echocardiography practices, disease prevalence and progression, referral patterns, and treatment pathways. Addressing these gaps is critical for improving patient care and informing clinical decision-making.\n\nSouth Korea provides a unique opportunity to conduct a nationwide retrospective echocardiographic study due to its advanced healthcare infrastructure, high patient volume, and strong tradition in clinical research. The current study aims to evaluate the real-world burden and clinical journey of patients with moderate or severe valvular disease over a 10-year period, based on echocardiographic and electronic medical record (EMR) data collected from multiple tertiary centers across the country.",[177,178,179,180,27,181,182,183],"Heart Valve Diseases","Aortic Valve Stenosis","Aortic Valve Insufficiency","Mitral Valve Insufficiency","Tricuspid Valve Insufficiency","Rheumatic Heart Disease","Aortic Diseases","NOT_YET_RECRUITING","2025-07-07",{"date":187,"type":33},"2025-07-16",{"date":189,"type":21},"2025-08",{"date":191,"type":21},"2027-12-31",{"name":193,"class":40},"Yonsei University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100572843","patient-centered-approach-for-treatment-decisions-in-mitral-valve-prolapse-100572843","NCT06738537","Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse","Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse (PRIMARY SDM)","PRIMARY SDM","Inclusion Criteria:\n\n* Age 21 years and older\n* Diagnosis of degenerative mitral valve regurgitation\n\nExclusion Criteria:\n\n* Non-English speaking\n* Unable to consent on own behalf\n* Previous mitral surgery","21 Years",{"count":73,"type":21},"This is a qualitative and quantitative study that seeks to obtain information from patients with degenerative mitral valve prolapse and providers regarding factors important in deciding between surgical mitral valve repair (MVR) and transcatheter edge-to-edge repair (TEER). Findings from this study will provide data that can be used to develop decision aids that can assist patients in decision making between these two therapies and assist providers in integrating shared decision making the within the multidisciplinary heart valve team.",[27],[207,208],"transcatheter edge-to-edge repair","surgical mitral valve repair","2024-12-16",{"date":211,"type":33},"2024-12-17",{"date":213,"type":33},"2023-09-01",{"date":215,"type":21},"2025-02-28",{"name":217,"class":40},"Northwell Health",5,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":225,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":41},"100573087","a-study-of-mitral-annular-disjunction-in-mitral-valve-prolapse-patients-and-arrhythmia-risk-100573087","NCT06741709","A Study of Mitral Annular Disjunction in Mitral Valve Prolapse Patients and Arrhythmia Risk","Inclusion Criteria:\n\n* All consecutive patients \\> 18 years of age presenting to Assiut University Heart Hospital with MVP and more than moderate MR.\n\nExclusion Criteria:\n\n* Previous mitral valve surgery.\n\n  * MVP due to infective endocarditis.\n  * Moderate or more significant aortic stenosis, aortic regurgitation or mitral stenosis.\n  * Congenital heart disease and poor image quality precluding accurate assessment of the mitral valve.","18 Months",{"count":227,"type":21},30,"This study investigates the characteristics and prevalence of mitral annular disjunction in patients with mitral valve prolapse with severe mitral regurgitation (MR) at Assiut University Heart Hospital.",[27,180],[231],"Mitral annular disjunction","2024-12-15",{"date":234,"type":33},"2024-12-19",{"date":236,"type":21},"2025-02-14",{"date":238,"type":21},"2026-12-30",{"name":240,"class":40},"Assiut University",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":41},"100294488","prognostic-impact-of-the-location-of-mitral-valve-prolapse-on-the-long-term-results-of-mitral-plasty-100294488","NCT03113552","Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty","IPPVM","Inclusion Criteria:\n\n* Patients operated between 1988 and 2011\n* Presence of a valvular prolapse diagnosed by echocardiography\n* Possibility of a complete clinical evaluation at the time of the initial echocardiography\n\nExclusion Criteria:\n\n* Ischemic MI (including papillary muscle rupture)\n* Presence of significant aortic valvulopathy, mitral valvular stenosis or congenital disease\n* History of cardiac surgery",{"count":249,"type":21},1500,"Mitral insufficiency (MI) accounts for 24% of adult valvulopathies and affects 7% of subjects older than 75 years. They are the second leading cause of valvulopathy in Europe. The most common etiology is the associated valvular prolapse. Mitral surgery remains the reference treatment for symptomatic MI. The success of this procedure depends on the mitral valve geometry and the location of the prolapse. The site of the prolapse, whether monovalvular, localized to the posterior or anterior leaflet, or bivalvular, influences the possibilities and probably the long-term results of the plasty.",[27,252],"Mitral Plasty","2023-05-22",{"date":255,"type":33},"2023-05-23",{"date":257,"type":33},"2013-02-04",{"date":259,"type":21},"2028-07-04",{"name":261,"class":40},"Centre Hospitalier Universitaire, Amiens",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":272,"studyType":52,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":218},"100377136","multicenter-post-market-observational-registry-of-the-neochord-artificial-chordae-delivery-system-100377136","NCT04190602","Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System","The AcChord Study: A Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System","AcChord","Inclusion Criteria:\n\n* Has Grade III Moderate or Grade IV Severe degenerative or mixed disease mitral valve regurgitation\n* Study procedure completed after 31 December 2016\n\nExclusion Criteria:\n\n* Heavily calcified valves\n* Valvular retraction with severely reduced mobility\n* Active bacterial endocarditis\n* Complex mechanism of MR (leaflet perforation, etc.)\n* Significant tethering of leaflets\n* Inflammatory valve disease",{"count":271,"type":21},500,"5 Years","The objective of this study is to evaluate the 5-year outcomes of participants with degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model DS1000 in a post-market setting.",[97,275,180,27,177],"Mitral Valve Disease",[277,278,279,280],"NeoChord","DS1000","Artificial Chordae","Mitral Valve Repair","2020-07-09",{"date":283,"type":33},"2020-07-10",{"date":285,"type":33},"2020-02-09",{"date":287,"type":21},"2027-12",{"name":277,"class":289},"INDUSTRY"]